Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect
Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect - Companies and Markets adds new report
© companiesandmarkets.com
26.11.2008 08:48:01 Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect - a new market research report on www.companiesandmarkets.com
(live-PR.com) - www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Stimulated by evidence of disease slowing with Teva/Lundbeck´s Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson´s disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
*This report gives a strategic analysis of the likely impact that recent events will
have on the future Parkinson´s disease market
*Includes Parkinson´s disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including Parkinson´s disease-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
Datamonitor has upgraded its forecasts of Teva/Lundbeck´s Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson´s disease drug at this time.
GlaxoSmithKline´s Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim´s Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB´s Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB´s misfortune.
Reasons to Purchase
*Understand the impact of recent and anticipated events on the Parkinson´s disease market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson´s disease-specific sales of key brands
www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Stimulated by evidence of disease slowing with Teva/Lundbeck´s Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson´s disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
*This report gives a strategic analysis of the likely impact that recent events will
|
|
*Includes Parkinson´s disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including Parkinson´s disease-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
Datamonitor has upgraded its forecasts of Teva/Lundbeck´s Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson´s disease drug at this time.
GlaxoSmithKline´s Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim´s Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB´s Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB´s misfortune.
Reasons to Purchase
*Understand the impact of recent and anticipated events on the Parkinson´s disease market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson´s disease-specific sales of key brands
www.companiesandmarkets.com/Summary-Market-Repor ..
| Author: |
